Wang Kai, Jin Lei-Yang, Zhang Qin-Guo
Department of Hepatobiliary Surgery, Zhuji People's Hospital, Zhuji 311800, Zhejiang Province, China.
Department of General Surgery, Zhuji Sixth People's Hospital, Zhuji 311800, Zhejiang Province, China.
World J Hepatol. 2025 Feb 27;17(2):103345. doi: 10.4254/wjh.v17.i2.103345.
This letter addresses the study by Jayabalan , which underscores the liver outcome score (LOS) and hemoglobin (Hb) as key prognostic markers for patients with autoimmune liver disease overlap syndromes (AILDOS), with particular relevance to the autoimmune hepatitis-primary biliary cholangitis (AIH-PBC) subgroup. The findings indicate that an LOS threshold of 6 achieves high sensitivity and specificity in predicting liver-related mortality among AIH-PBC patients. Moreover, low Hb levels emerge as a significant mortality predictor across all AILDOS cases. These results contribute valuable perspectives on risk stratification in AILDOS, highlighting the promise of non-invasive prognostic tools. Future studies with larger cohorts are needed to substantiate LOS and Hb as robust markers for clinical application.
这封信讨论了Jayabalan的研究，该研究强调肝脏结局评分（LOS）和血红蛋白（Hb）是自身免疫性肝病重叠综合征（AILDOS）患者的关键预后标志物，对自身免疫性肝炎-原发性胆汁性胆管炎（AIH-PBC）亚组尤为重要。研究结果表明，LOS阈值为6在预测AIH-PBC患者肝脏相关死亡率方面具有高敏感性和特异性。此外，低Hb水平在所有AILDOS病例中均为显著的死亡率预测指标。这些结果为AILDOS的风险分层提供了有价值的观点，突出了非侵入性预后工具的前景。需要更大样本量的队列研究来证实LOS和Hb作为临床应用中可靠标志物的作用。
